Pharmaceutical Administration Bureau has approved IASO Biotherapeutics’ new drug application (NDA) for equecabtagene ...

A clinical team has spearheaded the use of CAR-T cell therapy for blood cancers. The researchers recently treated the first ...

While teclistamab looks on course to be the first BCMA-targeting bispecific antibody to reach the market, Pfizer is hot on J&J's heels with its BCMAxCD3 drug elranatamab and reported phase 2 data ...

It joins a number of other BCMA-directed therapies for multiple myeloma, including GSK's first-to-market antibody-drug conjugate Blenrep (belantamab mafodotin), Bristol-Myers Squibb/bluebird bio's ...

Myeloma, or multiple myeloma, is a cancer affecting a particular type of blood cells, called plasma cells. Myeloma is most common in people over 60 and is characterized by the accumulation of ...

Multiple myeloma (MM) is the second most common hematological malignancy globally ... Equecabtagene Autoleucel is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene ...

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T entering Phase 3 ...